All In Biotech

NDA 208711 · Novartis

Egaten

Triclabendazole · Oral · Anthelmintic

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Feb 17, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Feb 13, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

3

1 Phase 3, 0 recruiting

FAERS reports

44

24 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 4, 2026.

EGATEN ® is indicated for the treatment of fascioliasis in patients 6 years of age and older. EGATEN ® tablet is an anthelmintic indicated for the treatment of fascioliasis in patients 6 years of age and older.

Mechanism: Triclabendazole is an anthelmintic against Fasciola species [see Microbiology (12.4)] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 13, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
  • EGATEN · TRICLABENDAZOLE 250MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Triclabendazole" as an intervention, any sponsor and status, largest first.

All 3 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malaise7
  • trematode infection5
  • fascioliasis4
  • condition aggravated3
  • illness3
  • nausea3
  • overdose3
  • rash3
  • abdominal pain2
  • chest pain2
  • cough2
  • diarrhoea2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20195
20209
20213
20225
20234
20246
202511

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 48 on PubMed

Sponsor: Novartis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.